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Title: Hyperprolactinaemia in First Episode Psychosis- A longitudinal assessment  
Abstract 
Little is known about hyperprolactinaemia (HPL) in first episode psychosis (FEP) patients. We 
investigated longitudinal changes in serum prolactin in FEP, and the relationship between HPL, 
and antipsychotic medication and stress.   
Serum prolactin was recorded in FEP patients at recruitment and again, 3 and 12 months later. 
HPL was defined as a serum prolactin level greater than 410 mIU/L (~19.3ng/ml) for males, and 
a serum prolactin level greater than 510 mIU/L (~24.1ng/ml) for females.  
From a total of 174 people with serum prolactin measurements at study recruitment, 43% 
(n=74) had HPL, whilst 27% (n=21/78) and 27% (n=26/95) had HPL at 3 and 12 months 
respectively.  We observed higher serum prolactin levels in females versus males (p<0.001), 
and in antipsychotic treated (n=68) versus antipsychotic naïve patients (p<0.0001).  Prolactin 
levels were consistently raised in FEP patients taking risperidone, amisulpride and FGAs 
compared to other antipsychotics.  No significant relationship was observed between perceived 
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stress scores (β=7.13, t =0.21, df=11, p=0.0.84 95% CI -72.91-87.16), or objective life stressors 
(β=-21.74, t=-0.31, df=8, p=0.77 95% CI -218.57-175.09) and serum prolactin.  
Our study found elevated rates of HPL over the course of the first 12 months of illness. We 
found no evidence to support the notion that stress is related to elevated serum prolactin at the 
onset of psychosis.  
Keywords: Prolactin; hyperprolactinaemia; first episode psychosis (FEP); schizophrenia; 
antipsychotics; stress  
4	  
	  
Title: Hyperprolactinaemia in First Episode Psychosis- A longitudinal assessment 
Hyperprolactinaemia (HPL) is a relatively common, but often unacknowledged side effect of 
antipsychotic medications. In general, all antipsychotic medication can be associated with HPL, 
with the propensity for an antipsychotic to cause HPL mainly associated with its degree of D-2 
receptor antagonism (Bushe et al., 2008a), and a higher ratio of pituitary to striatal D-2 receptor 
occupancy(Kapur et al., 2002). The highest prevalence of HPL is seen with amisulpride, 
risperidone, and paliperidone, even at relatively low doses, followed by the first generation 
antipsychotics (FGAs) (Bushe et al., 2008b).  A recent meta-analysis identified that 
standardised mean differences compared with placebo for prolactin increase varied from 0·22 
for aripiprazole (best drug) to –1·30 for paliperidone (Leucht et al., 2013). Hyperprolactinaemia 
is important to patients as it has been linked with sexual dysfunction, hypogonadism,(Howes et 
al., 2007) cancer and osteoporosis (De Hert et al., 2015; Howes et al., 2005; Meaney et al., 
2004; Peuskens et al., 2014). 
There is a paucity of information on the prevalence of hyperprolactinaemia in early psychosis, 
particularly among those who are antipsychotic naïve. The largest study in early psychosis 
identified that 74% of patients treated with risperidone had HPL at some point over a two year 
period(Schooler et al., 2005), while HPL rates of 71% were identified in the European First 
Episode Schizophrenia (EUFEST) study, half of those being antipsychotic naïve (Kahn et al., 
2008). In two cross sectional studies of antipsychotic naïve FEP patients, 29-39% were 
identified as having HPL (Aston et al., 2010; Riecher-Rössler et al., 2013). A recent meta-
analysis of prolactin in antipsychotic-naïve patients, found significantly elevated prolactin levels 
in both males and females, though the findings were limited by the small number of identified 
studies (Gonzalez-Blanco et al., 2016).   
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The heightened prevalence of HPL, even in antipsychotic naïve FEP patients, does  not appear 
to be attributable to important confounding variables such as sex, smoking status, body mass 
index (BMI), thyroid stimulating hormone or ghrelin (Garcia-Rizo et al., 2012). This has led some 
to hypothesise that stress may be causative of HPL, which may in turn be a contributing factor 
to the emergence of the psychotic episode (Howes and Kapur, 2009; Riecher-Rössler et al., 
2013). A postulated mechanism suggests that increased dopamine in psychosis may in part be 
due to its role as a prolactin-inhibiting factor (PIF), and as part of a regulatory mechanism to 
down regulate excess prolactin which has been caused by stress (Riecher-Rössler et al., 2013). 
However, this hypothesis regarding the relationship between stress and HPL has not yet been 
tested in a FEP group of patients.  
1.1 Aims of the study 
Given the paucity of longitudinal research investigating HPL in people with early psychosis 
(Pérez-Iglesias et al., 2012), we set out to investigate the prevalence of HPL during the first year 
of treatment for psychosis.  Specifically, we set out to examine a) the relationship between HPL 
and antipsychotic medication use, gender, ethnicity, age, smoking and psychopathology at the 
time of the study recruitment; b) to evaluate any differences in serum prolactin levels and HPL 
among antipsychotic naïve and antipsychotic treated patients. For the first time, we aimed to 
elucidate any associations of perceived stress and stressful life events with serum prolactin in 
antipsychotic naïve patients.  
Methods 
Subjects were recruited in the context of the Physical Health and Substance Use Measures in 
First Onset Psychosis (PUMP) study, part of the NIHR funded IMPaCT programme. PUMP is a 
naturalistic longitudinal study assessing the relationship between lifestyle habits and the 
emergence of cardiometabolic risk over the first year of psychosis. The study was approved by 
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the Joint South London and Maudsley and The Institute of Psychiatry NHS Research Ethics 
Committee (REC reference number:08/H0807/53). 
2.1 Eligibility criteria 
Study participants were required to meet the ICD-10 criteria for FEP (codes F20-29 and F30-
33)(World Health Organization, 1992)and were aged between 18 and 65. The baseline 
diagnoses were made from face-to-face interviews and mental health records according to ICD-
10 criteria (WHO, 1992) utilising the Operational Criteria Checklists (OPCRIT)(McGuffin et al., 
1991). Individuals with comorbid substance use disorders were not excluded. We excluded 
individuals who met the criteria for organic psychosis (F09) or moderate or severe learning 
disabilities(as defined by ICD-10, World Health Organization, 1992) (World Health Organization, 
1992), who presented with evidence of transient psychotic symptoms resulting from acute 
intoxication as defined by ICD-10, and who were pregnant. 
2.2 Recruitment 
Patients were recruited as soon after first presentation as possible and were followed up 
prospectively over a twelve month period during which they remained under the care of mental 
health teams.  Antipsychotic medication changes were made by the treating psychiatrists as 
part of routine clinical care over the course of the follow up period.  
2.3 Serum prolactin measurement and hyperprolactinaemia definition 
There are a variety of reported units of measurement for serum prolactin levels. Studies 
performed outside of the UK generally report data as ng/ml, whereas most UK data is in mIU/L 
(the accepted SI unit for prolactin measurement). We measured serum prolactin levels in mIU/L, 
but have also presented data in ng/ml, calculated on the basis of 1ng/ml equalling 21.2 mIU/L 
(Bushe et al., 2008a). All serum prolactin measurements were performed by the same 
laboratory and a fasting sample was taken in the morning by direct venepuncture without regard 
to timing of medication in those who were already treated with antipsychotics.  
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Quantitative determination of prolactin serum levels were evaluated by a direct 
chemiluminometric method using The ADVIA Centaur® Prolactin assay, which is a two-site 
sandwich immunoassay. A direct relationship exists between the amount of prolactin present in 
the patient sample and the amount of relative light units detected by the system. Intraassay and 
interassay coefficients of variation for serum prolactin are 2.75% and 3.60% (Bayer 
Diagnostics). 
Hyperprolactinaemia was defined in accordance with the hospital laboratory reference range as 
a serum prolactin level greater than 410 mIU/L (~19.3ng/ml) for males, and a serum prolactin 
level greater than 510 mIU/L (~24.1ng/ml) females. In order to highlight the severity of HPL, we 
further categorised HPL into those with a serum prolactin above 1000mIU/L(~47.4ng/ml) and a 
serum prolactin level greater than 2000mIU/L (~94.8ng/ml). Although arbitrary, this 
categorisation has been implemented previously in a population with multi-episode 
schizophrenia (Bushe et al., 2008b), and mirrors previously defined serum prolactin cut offs 
linked to clinical symptoms, and those commonly used in endocrine practice. 
2.4 Antipsychotic medication use 
Subjects were interviewed in detail about antipsychotics they were taking at the time of blood 
sampling. Also, medical records were taken into account to obtain the date when antipsychotic 
medication was initiated.  
Antipsychotic medication doses were standardised as defined daily doses (DDD) based on the 
dose prescribed at the time of the prolactin measures (WHO Collaborating Centre for Drug 
Statistics Methodology, 2015).  Additionally, the duration of antipsychotic medication use in days 
prior to study recruitment and from study recruitment to the end of the follow up period was 
recorded.  
2.5 Demographic data and clinical outcome measures 
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Baseline data included demographics, diagnoses, antipsychotic status, treatment setting, and 
smoking status. The severity of psychopathology was rated on the Positive and Negative 
Symptom Scale (PANSS)(Kay et al., 1989) and by the Global Assessment of Functioning (GAF) 
scale at first presentation for psychosis.   
The perceived stress scale (Cohen et al., 1983) was used to measure the participants appraisal 
of how stressful events in their lives were at study recruitment. The brief life event (BLE) 
questionnaire (also known as the list of threatening experiences (LTE) questionnaire) was used 
to measure objective recent life stressors (Brugha and Cragg, 1990). 
 
2.6 Data Analysis 
Between groups comparisons were made using x2 test for categorical variables; independent 
student’s t-test for continuous variables, or the Mann-Whitney U test if variables were not 
normally distributed.  
Linear regression was used to test the hypothesis that stress was related to prolactin levels, by 
examining the association between serum prolactin levels and the Perceived Stress Scale and 
the BLE total score, controlling for potential confounding factors of gender, age and ethnicity. 
Statistical significance was defined as p<0.05. All analyses were conducted in STATA release 
12 (STATACorp LP, USA). 
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3. Results 
 
3.1. Sample characteristics 
174 FEP patients had a serum prolactin measure at baseline and were included in this study. 
Clinical and demographic characteristics of the study population are shown in table 1. Sixty four 
percent (n=112) of this population was male. The mean age (SD) of the participants was 29.8 
years (SD=10.2) (range 17-61 years). Seventeen percent (n=28 out of 167 with antipsychotic 
medication data) were antipsychotic naive at study recruitment. The mean duration of 
antipsychotic treatment at study recruitment in the 139 others was 50.0 days (SD=43.6, range 
=1-193 days pre blood measure), 22 (16%) of whom received exclusively low risk of HPL 
antipsychotics (i.e. aripiprazole), with 40 (29%) receiving antipsychotics associated with a high 
risk of HPL (i.e. amisulpride, risperidone, FGAs) and 77 (55%) who had been prescribed 
antipsychotics with an intermediate or medium risk of HPL (i.e. olanzapine, quetiapine).  All 
were treated with antipsychotic monotherapy at study recruitment. The DDDs for antipsychotic 
medication at study recruitment and at follow up are shown in supplementary table 1. 
INSERT TABLE 1 HERE 
3.2 Hyperprolactinaemia (HPL) prevalence rates 
At study recruitment, HPL was found among 43% (95% CI=35-49.9%) (n=74) of patients at 
recruitment; in 27% (95%CI=16.6-36.5) (n=21) at 3 months and in 27% (18.2-36.5) (n=26) at 12 
months.  
Prevalence rates of HPL according to antipsychotic status and sociodemographic and clinical 
characteristics are shown in Table 2.  
INSERT TABLE 2 HERE 
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Prolactin levels above 1000mIU/L (~47.4ng/ml) were found in 16% (n=27) of patients at study 
recruitment, with 5% (n=8) at study recruitment having a prolactin of greater than 2000mIU/L 
(~94.8ng/ml) (exclusively female).  Seven of those with HPL > 2000mIU/L (~94.8ng/ml) had 
been treated with antipsychotic medication at study recruitment (amisulpride=2; olanzapine=1; 
aripiprazole=2; risperidone =2) for a mean of 50.1 days (SD=46.6; range 11-146 days), while 
the remaining patient was antipsychotic naive. At follow up two non-antipsychotic treated 
females had a prolactin level > 2000mUI/L (~94.8ng/ml) (both with previous antipsychotic 
medication discontinued for more than 100 days).  
At study recruitment, females had significantly higher serum prolactin levels (mean=706.6mIU/L 
(SD=807.6) (~33.5ng/ml (SD=38.3)) compared to males (mean prolactin of 238.5 mIU/L (146.9) 
(~11.3ng/ml(SD=6.9)) (Mann-Whitney U test  =-3.91, p<0.0001). Females were not more likely 
to be prescribed antipsychotics with a high risk of causing HPL at study recruitment (T1-F:M 
25%vs31%;p=0.45). However, the prevalence of HPL at all three time points did not differ by 
gender (T1-M:F-40% vs 47% p=0.25; T2-M:F- 31% vs 20%, p=0.22; T3-M:F- 31% vs 21%, 
p=0.19).  
3.3 Antipsychotic effects 
Patients were treated with up to eight different antipsychotic medications over the course of the 
year. Fifty seven percent (n=95) of those treated with an antipsychotic medication at recruitment 
remained on the same antipsychotic over the year.  
Figures 1 and 2 shows mean serum prolactin levels and the prevalence of HPL in antipsychotic 
treated patients at all three timepoints.  
INSERT Figures 1&2 HERE 
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Forty nine percent (n=68) of antipsychotic treated patients had HPL at study recruitment, which 
was significantly higher than 11% (n=3) of the antipsychotic naïve patients with HPL (OR=7.9 
(95% CI 2.29-27.49) p<0.001).  
There was no significant association between the mean DDDs of antipsychotic medication in 
those with HPL at study recruitment compared to those with no HPL (T1 HPL-DDD=0.95 
(SD=0.64); T1 No HPL- DDD=0.96 (0.67) (t=0.130, df=137, p=0.897).  Similarly at follow up 
(T3), the mean DDD was not significantly different in those with HPL (mean DD=1.05 
(SD=0.60)) compared with those with no HPL (mean DDD=1.08 (SD=0.54)) (t=0.181, df=57, 
p=0.857). 
Those with HPL at study recruitment had similar durations of antipsychotic treatment 
(mean=46.6 days (SD41.8)) compared to those without HPL (mean=53.3 days (SD 45.3) 
(t=0.896, df=133, p=0.37). Neither was duration of antipsychotic use associated with HPL at 
follow up (T3) (T3 HPL : mean duration of antipsychotic use =391.6 days(SD=153.2); T3 with no  
HPL: mean duration of antipsychotic use =421.3 days (SD=177.3) (t=0.726, df=81, p=0.47).	   
Figure 3 shows mean serum prolactin levels for those who remained on the same antipsychotic 
medications over the study period. Those continuously treated with risperidone (n=14) over the 
year had diminishing serum prolactin levels over the study period (with a rate of HPL of 70% at 
study recruitment and 40% at 12 months). There was a similar effect in those who remained on 
olanzapine over the year, with HPL rates of 42% at study recruitment, 24% at 3 months and 
16% at 12 months. Prolactin levels were higher in those treated with risperidone, amisulpride or 
FGAs compared to those treated with olanzapine, quetiapine or aripiprazole at all time-points 
(T1: F(6, 84)=11.9 p<0.001 T2: F(5, 33)=20.0 p<0001; T3: F(5, 45)=1.30 p=0.28). 
INSERT Figure 3 HERE 
3.4 Influence of perceived stress and psychopathology 
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Patients with HPL had more severe clinical symptoms, as identified by a significantly lower GAF 
symptom score (52.9 (18.0) at presentation, compared to those with no HPL (59.4 (16.7)) 
(t=2.15, df=131, p=0.03). This was not accounted for by increased mean DDDs of antipsychotic 
medication in those with HPL (see above). 
Serum prolactin levels in the antipsychotic naïve group at study recruitment were not associated 
with perceived stress scores (β=7.13, t =0.21, df=11, p=0.0.84 95% CI -72.91-87.16), or BLE 
scores (β=-21.74, t=-0.31,df=8, p=0.77 95% CI -218.57-175.09,). Similarly serum prolactin 
levels in the antipsychotic treated group were not associated with perceived stress scores 
(β=11.7, t =0.81, df =75, p=0.418 95% CI -16.97-40.39) or BLE scores (β=17.7, t =0.83, df=78, 
p=0.41 95% CI -25.03-60.52). 
There was no elevation in perceived stress levels between those patients with FEP who were 
hospitalised at study recruitment compared to those who were treated in the community. 
4. Discussion 
The current study is to our knowledge the first naturalistic study in FEP to investigate the 
prevalence of HPL in categorical terms using a longitudinal design. In this study we demonstrate 
elevated rates of HPL in both antipsychotic treated and untreated patients with FEP, with 43% 
meeting criteria for HPL at study recruitment.  The current study is also the first to investigate 
stress and its relationship with prolactin in FEP; we did not determine any effect. 
We chose to present our findings in categorical terms (along with mean values), in order to 
optimise the clinical utility of the data. In relation to this we categorised HPL by rates of severity 
(HPL >1000mIU/L (~47.4ng/ml) and >2000>mIU/L (~94.8ng/ml)), with 16% demonstrating HPL 
>1000mIU/L (~47.4ng/ml) at baseline and 11% at 12 months. These rates are similar to those 
identified in patients receiving maintenance antipsychotic treatment for schizophrenia (Bushe 
and Shaw, 2007; Bushe et al., 2008b).  
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The prevalence of HPL for those patients who were antipsychotic naïve was 11%, a lower rate 
than found in other samples of antipsychotic naive FEP patients (Aston et al., 2010; Riecher-
Rössler et al., 2013), though substantially higher than rates of 0.4% in the general 
population(Biller et al., 1999). However, the finding that 11% of those who were antipsychotic 
naive had evidence of HPL at baseline reinforces the need for prolactin measures to be 
measured before any antipsychotic treatment is started to ensure that HPL is not a pre-existing 
state(Peuskens et al., 2014). Our finding of higher mean serum prolactin levels in females is 
consistent with previous literature in established psychosis(Bushe et al., 2008a), and is 
expected given that females are primed to respond to prolactin during physiological states such 
as pregnancy and breast feeding. 
4.1 Antipsychotics and HPL 
In relation to antipsychotic treatment, we identified large amounts of treatment switching during 
the course of the first twelve months of illness, with just over half of the patients maintained on 
the same treatment over the 12 month period (n=95; 57%). 
We confirmed that risperidone, along with amisulpride and FGAs (though these findings are 
limited by the small numbers) are more potently associated with increased prolactin levels in 
FEP than other antipsychotics. However, all antipsychotics, including aripiprazole, were 
associated with HPL at some point over the 12 month period.  However, due to frequent 
changes in antipsychotics, attributing and isolating the corresponding HPL to any given 
medication is challenging.  Nevertheless, we identified that the highest prevalence rate for HPL 
associated with risperidone was seen at study recruitment (70% with HPL), followed by a 
decline in rates of HPL over the study period (40% of those patients treated continuously from 
baseline with risperidone had HPL at the end of the study period). Forty two percent of 
olanzapine treated patients had HPL at study recruitment, one quarter had HPL at 3 months, 
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and only 16% had HPL at the end of the study period. This declining prevalence of HPL in 
continuously used antipsychotics has previously been demonstrated in FEP with the use of 
olanzapine, haloperidol and risperidone (Pérez-Iglesias et al., 2012). It has been previously 
suggested that prolactin can induce a negative feedback on its own secretion, a possible 
explanation for the declining HPL prevalence (Grattan et al., 2001). Further, medication non 
adherence during follow up may have been a contributing factor to the declining rates of HPL. 
Despite long antipsychotic exposure, there was no significant effect of antipsychotic treatment 
duration on rates of HPL at follow up (nor at study recruitment). Further, we did not identify a 
dose effect of antipsychotics with HPL, with higher DDDs not associated with increased rates of 
HPL at study recruitment or at follow up. These findings indicate that neither the cumulative 
effect of antipsychotic exposure nor the dose of antipsychotic used is associated with the 
emergence (or persistence) of HPL.  
Our finding that amisulpride was associated with HPL in all patients across the study period, is 
consistent with previous studies identifying substantial increases in serum prolactin and rates of 
HPL in FEP with amisulpride use (Kahn et al., 2008; Peuskens et al., 2014). We identified a 
HPL rate of 25% for aripiprazole monotherapy (continuous use over the study period) at the end 
of the follow period. The elevations in prolactin seen in aripiprazole treated patients are 
somewhat surprising, though previous studies have found HPL rates of 10% in FEP patients 
treated with aripiprazole(Kwon et al., 2009).  Even though aripiprazole has perhaps the most 
benign impact of all antipsychotic medication on prolactin measures (Leucht et al., 2013), our 
findings indicate that in some patients HPL can still occur.  
The course and persistence of HPL in relation to antipsychotic use overtime remains a complex 
question, and one with which the literature is limited by a lack of prospective studies (Eberhard 
et al., 2007; Pérez-Iglesias et al., 2012). However, our naturalistic study provides further 
evidence that rates of HPL do decline over the first year of illness, but that HPL persists with all 
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antipsychotics used, with higher rates of sustained HPL seen with amisulpride, risperidone and 
FGAs. 
4.2 Stress, Symptoms and HPL 
We did not find evidence supporting the hypothesis that stress induced HPL may play a role in 
the emergence of FEP. There was no evidence of an association between perceived stress or 
objective life stressors and HPL, either in the antipsychotic treated or in the antipsychotic naïve 
groups. We were able to measure the patients’ perceived stress at the time of study recruitment, 
and also relate this to stressful life events experienced over the preceding weeks or months- 
meaning that we were able to comprehensively assess serum prolactin levels in the context of 
patient’s stressors and their experience of them after the onset of the psychotic episode.  
However, our null finding in this regard may possibly be due to limitations in the data, including 
the sample size. 
Our lack of association between psychotic symptoms and HPL is consistent with earlier findings 
in FEP, though this remains a poorly researched area (Riecher-Rössler et al., 2013). For the 
first time we have identified an association between HPL in the early stages of FEP and a 
reduced level of functioning as measured by GAF, compared to those FEP patients with no 
HPL. Further, we did not find an association between higher antipsychotic DDDs and HPL rates, 
thus reducing the chance that this finding of an association between HPL and lower GAF scores 
was a case of cofounding by indication (i.e. those with a more severe illness presentation might 
have received higher doses of antipsychotics, thereby increasing their risk of HPL). 
4.3 Strengths 
This is the largest naturalistic study in FEP to report on the prevalence of HPL over the first year 
of illness. The use of categorised HPL data ensures that our findings have clinical applicability. 
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Serum prolactin levels were measured in the same laboratory for all patients, thus enhancing 
the standardisation of the prolactin results.  
4.4 Limitations 
We acknowledge that our findings in this group are limited by the lack of homogeneity inherent 
to a FEP population of patients. A limitation of our study is the relatively high number of 
participants who did not have a prolactin measure at study follow up (45% (n=79) at follow up 
with no prolactin measure). There was no association identified between serum prolactin and 
stress in antipsychotic naïve patients, though caution is required in the interpretation of this 
finding due to the small numbers of cases. We did not measure medication adherence over the 
study period, raising the possibility that non adherence may have contributed to our finding of a 
lack of dose effect between antipsychotic use and HPL, and which may have distorted the 
associations between antipsychotics and HPL. 
We did not record the timing of antipsychotic administration in relation to prolactin 
measurement. We attempted to sample all patients in the fasting state, but this was not always 
feasible, and we had to sample some patients later in the day according to their availability. As 
this situation mirrors the realities of managing patients with psychosis, we believe that our data 
on HPL remain applicable to clinical practice. We did not measure thyroid status in patients, a 
potential confounding factor for a minority of those with HPL. Nor did we record symptoms 
which may be related to raised serum prolactin, such as sexual dysfunction or menstrual 
abnormalities, data which may have further increased the clinical relevance of our findings.  
4.5 Implications for practice 
In recent years, the occurrence of cardiometabolic risk factors has been more prominently 
recognised in psychotic disorders (Mitchell et al., 2013). However, the routine monitoring of 
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serum prolactin levels is not included in the most recent UK guidelines as part of ongoing 
monitoring of physical health side effects of antipsychotic treatment (NICE., 2014).  
The high rates of HPL identified in this study indicate that serum prolactin measures should be 
routinely incorporated into baseline assessments before the start of any antipsychotic treatment, 
including before a switch to a new antipsychotic. Monitoring for prolactin levels should be 
incorporated into established fasting blood sampling at all stages of antipsychotic treatment. If 
prolactin is already raised at baseline, then prolactin sparing antipsychotics are preferentially 
used (e.g. aripiprazole and asenapine).  
Further, in recent years, it has become more widely recognised that sustained 
hyperprolactinaemia can have longer term adverse effect potential, primarily mediated by 
inhibition of the hypothalamopituitary-gonadal axis.  These effects are particularly marked on 
bone integrity, increasing the risk for low bone mineral density(Crews and Howes, 2012), 
osteoporosis(O'Keane, 2008), and osteoporotic fractures(Stubbs et al., 2015).These effects 
could be additive to those of low vitamin D, commonly seen in psychosis (Crews et al., 2013; 
Lally et al., 2016). Our findings of high rates of HPL in this young population of antipsychotic 
treated patients, is important given the putative detrimental effect on bone mineral 
density(Crews and Howes, 2012), and the fact that exposure to antipsychotic medication and 
hyperprolactinaemia is likely to be present over a prolonged period of time. However, given the 
multifactorial aetiology for many of these adverse effects, uncertainty relating to the specific 
physical effects of hyperprolactinaemia persists, and probably contributes to the low level of 
monitoring which occurs in clinical practice. 
4.6 Management during antipsychotic treatment 
While in the majority of cases, HPL in FEP is likely to be related to physiological and 
medication-related causes, consideration should also be given to the possibility of a primary 
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endocrinology cause, with a prevalence of HPL in the general population of 0.4%(Biller et al., 
1999). 
Consideration should be given to any past history of symptoms that might suggest pituitary 
disease prior to the onset of psychosis and antipsychotic medication use, particularly a history 
of menstrual disturbance in women or erectile dysfunction in men, but also less common 
symptoms including headache and visual disturbance.  
It is helpful to establish the temporal relationship of the change in the prolactin level to the 
initiation of the antipsychotic. If there has been a clear change in prolactin following the 
introduction of the antipsychotic, and no prior symptoms of pituitary disease, then further 
investigation is not required, Provided the patient is asymptomatic, consideration for 
continuation of the antipsychotic can be made.  
Initial investigations in female patients with HPL should include a pregnancy test. Other relevant 
investigations include renal, liver and thyroid function tests and measurement of oestradiol or 
testosterone in those with symptoms suggestive of hypogonadism  A serum prolactin level of > 
2000mIU/L(~94.8ng/ml) can occur with antipsychotic medication, but a level of >2500mIU/L 
(~117.9ng/ml), in the absence of pregnancy or breast-feeding, should prompt an endocrinology 
referral for further investigation to exclude a micro or macro pituitary adenoma(Haddad and 
Wieck, 2004).  
All patients should be questioned about their sexual functioning in the context of an abnormal 
prolactin, and the finding of an abnormal prolactin level provides an opportunity, or prompt, to do 
so. This is important, as sexual dysfunction has been associated with increased dissatisfaction, 
and reduced compliance with medication (Lambert et al., 2004), and acknowledging and 
managing this is an important adherence maintenance intervention.   
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If a patient is asymptomatic, and not reporting disrupted menstruation (for women) or sexual 
dysfunction, then simple reassurance may be the most appropriate response, as many HPLs in 
FEP will improve with time, as identified in our and other studies (Brown and Laughren, 1981; 
Pérez-Iglesias et al., 2012). However, if sexual dysfunction is present then consideration for a 
dose reduction or a switch to an antipsychotic with a lower risk of causing HPL should be made. 
If a switch of antipsychotic is deemed to carry too great a risk of psychotic relapse, then the 
introduction of low dose aripiprazole to the current antipsychotic could be considered, as it is 
associated with reduction in serum prolactin levels (Shim et al., 2007). For those with HPL and 
confirmed secondary hypogonadism, oestrogen and testosterone replacement may improve 
symptoms and may counter against the risk of longer term skeletal effects of HPL (Melmed et 
al., 2011). 
 
4.7 Conclusions 
We found no relationship between HPL and perceived stress, thus failing to provide support for 
the prolactin/stress model of early psychosis.  However, HPL is often present at the time of FEP 
and is associated with the use of all antipsychotics, and is more prominent with the use of 
amisulpride, FGAs and risperidone, with rates plateauing at 12 months but remaining high. This 
has been a consistent finding in studies of maintenance treatment in schizophrenia, and while 
emerging evidence indicates that it occurs in FEP populations as well, this study confirms these 
findings. 
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Table 1 Demographic, diagnostic and prolactin level data for the overall sample (n=174); the subgroup 
receiving antipsychotic medications (n=139); and antipsychotic naïve subgroup (n=28) 
	  
	  
Demographic, diagnostic and 
prolactin level 
Overall 
sample 
(n=174) 
Antipsychoti
c naïve 
(n=28; 
16.8%) 
Antipsychotic 
subgroup 
(n=139; 
83.2%) 
Comparisons between 
antipsychotic vs 
antipsychotic naïve 
subgroups 
Age years     
Test-
statistic df p-value 
 Mean years (SD) 29.3 (10.0) 31.2 (11.4) 29.0 (9.7) 0.65a  0.51 
 Range years   17-61 18-56 17-61    
         
  Men 28.2 (9.4) 29.4 (9.6) 28.0 (9.4) 0.61 a  0.53 
  Women  31.0 (10.6) 34.1 (14.0) 30.5 (10.0) 0.43 a  0.67 
         
Gender n(%)     0.28b 1 0.38 
 Male   112(64.4%) 19 (67.9%) 87 (62.6%)    
 Female   62 (35.6%) 9 (32.1%) 52 (37.4%)    
         
Ethnicity n(%)    0.45 b 2 0.83 
 White   80 (46.2%) 13 (46.4%) 62 (44.9%)    
 Black   62 (35.8%) 11 (39.3%) 49 (35.5%)    
 Other   31 (17.9%) 4 (14.3%) 27 (19.6%)    
         
Prolactin level     -3.28 a  0.001 
 
Mean mIU/L (SD) 
Mean ng/ml (SD) 
 
 
457.9 
(646.7) 
21.2 (30.5) 
352.7 
(571.3) 
16.6 (26.9) 
694.7 
(801.6) 
32.8 (37.8) 
   
 Range mIU/L Range ng/ml  
71-4047 
(3.3-190.9) 
108-3117 
(5.1-147.0) 
71-4047 
(3.3-190.9)    
         
Patients with prolactin elevation 
n(%)       
 All  74 (42.5%) 3 (10.7%) 68 (48.9%) 13.92 b 1 <0.001 
 Men   45 (40.2%) 2 (10.5%) 41 (47.1%) 8.66 b 1 0.002 
 Women   29 (46.8%) 1 (11.1%) 27 (51.9%) 5.15 b 1 0.02 
         
Diagnoses n(%)     0.59 b 1 0.32 
 Affective psychosis   32 (45.1) 7 (53.8) 24 (42.1)    
 Non-affective  39 (54.9) 6 (46.2) 33 (57.9)    
         
Antipsychotic medication n(%)       
 None  28 (16.8%) 28 (100%)     
 Olanzapine  64 (38.3%)  64 (46.0%)    
 Quetiapine  13 (7.8%)  13 (9.4%)    
 Risperidone  32 (19.2%)  32 (23.0%)    
 Aripiprazole  22 (13.2%)  22 (15.8%)    
 FGA  4 (2.4%)  4 (2.9%)    
 Amisulpride  4 (2.4%)  4 (2.9%)    
         
PANSS       
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 Total  Mean (SD) 58.7 (13.2) 55.5 (9.7) 59.2 (13.7) -1.08
c 122 0.28 
 Positive symptoms  
Mean 
(SD) 14.4 (5.6) 14.1 (3.8) 14.5 (5.8) 0.23
 a  0.82 
 Negative symptoms  
Mean 
(SD) 14.6 (5.7) 12.7 (4.2) 15.0 (5.9) -1.32
 a  0.19 
         
Perceived stress scale        
  Mean (SD) 13.6 (7.2) 17.6 (9.4) 13.0 (6.6) 1.61
 a  0.11 
Life events scale        
  Mean (SD) 5.0 (4.7) 7.1 (6.0) 4.8 (4.5) 1.19
 a  0.23 
GAF scores        
 GAF disability  Mean (SD) 29.4 (13.1) 28.4 (14.0) 31.8 (16.6) -1.07
 a  0.28 
 GAF symptoms  Mean (SD) 57.0 918.0) 70.4 (20.0) 55.1 (17.0) 2.68
 a  0.007 
	  
df, degrees of freedom; SD, standard deviation;  
 
a Mann-Whitney U test for non-paramedic continuous variables 
b x2 test for categorical variables 
c Independent student’s t-test for paramedic continuous variables 
	  
	  
Table 2. Prevalence of hyperprolactinaemia in first episode patients by risk factors at baseline  
	  
	  
Demographic, diagnostic 
and antipsychotics 
No Abnormal 
hyperprolactinaemia at 
baseline 
(n=100, 57.5%) 
Abnormal 
hyperprolactinaemia at 
baseline 
(n=74, 42.5%) 
   
  Mean (SD)/n(%) Mean (SD)/n(%) Test-statistic df p-value 
Ethnicity       
 White British  53 (66.3%) 27 (33.7%) 5.04 a 2 0.08 
 Black (all categories)  30 (48.4%) 32 (51.6%)    
 Other  16 (51.6%) 15 (48.4%)    
       
Gender       
 Male  67 (59.8%) 45 (40.2%) 0.71 a 1 0.25 
 Female  33 (53.2%) 29 (46.8%)    
       
Age years  30.10 (10.74) 28.88 (9.71) 0.57 b  0.57 
       
Smoking status       
 No  11 (50.0%) 11 (50.0%) 0.56 a 1 0.30 
 Yes  57 (58.8%) 40 (41.2%)    
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PANSS      
 Total  57.5 (12.8) 60.8 (14.5) -1.40 c 127 0.16 
 Positive symptoms  13.95 (5.83) 15.23 (5.31) -1.77 b  0.08 
 Negative symptoms  14.13 (5.18) 15.48 (6.35) -1.01 b  0.31 
       
Perceived stress scale  13.86 (7.31) 13.40 (7.08) 0.34 b  0.73 
       
Life events scale 4.84 (4.39) 4.73 (4.59) 0.28 b  0.78 
       
GAF scores       
 GAF disability  30.66 (16.99) 30.78 (14.99) -0.05 c 166 0.96 
 GAF symptoms  59.43 (16.72) 52.85 (17.99) 2.15 c 131 0.03 
       
Diagnosis       
 Affective psychosis  27 (69.3%) 12 (30.7%) 3.25 a 1 0.05 
 Non-affective 36 (51.4%) 34 (49.6%)    
       
Antipsychotic medications    17.9 a 5 0.001 
 Olanzapine 33 (51.6%) 31 (48.4%)    
 Quetiapine 3 (23.1%) 10 (76.9%)    
 Risperidone 9 (28.1%) 23 (71.9%)    
 Aripiprazole 18 (81.8%) 4(18.2%)    
 FGA 1 (25%) 3 (4.2%)    
 Amisulpride - 4 (100.0%)    
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Supplementary Table 1.  Mean antipsychotic medication doses at study recruitment and follow up 
	  
 
T1 mean AP 
dose (SD) 
(mg) 
T1 AP 
doses 
expressed 
as DDDs  
T3 APs 
(n=104) 
T3 mean AP 
dose (mg)    
T3 AP doses 
expressed as 
DDDs   
      
Olanzapine (n=64) 
 
12.8 (5.3) 
 
1.26 (0.53) 44 
 
13.3 (5.8) 
 
1.30 (0.52) 
      
Quetiapine (n=13) 
 
353.8 (211.6) 
 
0.97 (0.52)  14 
 
339.3 (190.3) 
 
0.85 (0.48) 
      
Risperidone (n=32) 
 
2.5 (1.0) 
 
0.50 (0.21) 19 
 
3.1 (1.2) 
 
0.65 (0.26) 
      
Aripiprazole (n=22) 
 
10.9 (5.5) 
 
0.73 (0.37) 19 
 
14.7 (7.0) 
 
0.99 (0.46) 
      
FGAs (n=4)  1.40 (0.98) 5  1.40 (0.87) 
 
Amisulpride (n=4) 
 
 
425.0 (150) 
 
 
1.07 (0.38) 
 
3 
 
 
216.7 (104.1) 
 
 
0.54 (0.26) 
      
	  
AP=antipsychotic 
DDDs-Defined daily doses
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